Empagliflozin Impact on Hemodynamics in Patients With Heart Failure



Status:Recruiting
Conditions:Cardiology
Therapuetic Areas:Cardiology / Vascular Diseases
Healthy:No
Age Range:19 - 119
Updated:4/6/2019
Start Date:July 5, 2017
End Date:December 2019
Contact:Sheryl Windsor
Email:EMBRACE-HF@saint-lukes.org
Phone:8169329858

Use our guide to learn which trials are right for you!

Empagliflozin Evaluation by Measuring Impact on Hemodynamics in Patients With Heart Failure

The primary purpose of this trial is to evaluate the impact of empagliflozin, as compared
with placebo, on hemodynamic parameters (pulmonary artery diastolic pressure) in patients
with heart failure (reduced or preserved ejection fraction, ischemic or non-ischemic
etiology) who already have a CardioMEMs device implanted for non-study related clinical
reasons.

A 12-week randomized, double-blind, placebo-controlled trial to explore the effects of
once-daily empagliflozin 10mg on hemodynamic parameters (pulmonary artery pressures) in
patients with heart failure (reduced or preserved ejection fraction, ischemic or non-ischemic
etiology) who already have a CardioMEMs device implanted for non-study related clinical
reasons.

Inclusion Criteria:

1. Established diagnosis of heart failure (for at least 16 weeks prior to the screening
visit) with either preserved (LVEF>40%) or reduced systolic function (LVEF≤40%), due
to either ischemic or non-ischemic etiology, documented by an imaging modality
(echocardiography, nuclear imaging, LV angiography, magnetic resonance imaging) within
the past 24 months.

2. No major change in diuretic management for 48 hours prior to screening visit or 48
hours prior to randomization visit (major change defined by doubling of diuretic dose
or addition of another diuretic medication)

3. NYHA class II, III or IV heart failure symptoms at the screening and randomization
visit

4. Presence of previously (≥ 2 weeks prior to screening visit) implanted CardioMEMs
pulmonary artery pressure monitor for a clinical indication unrelated to the study.

5. PA diastolic pressure ≥ 12 mmHg at the time of the screening visit (last measurement
available prior to the screening visit).

6. Ability to provide informed consent prior to initiating screening visit procedures

Exclusion Criteria:

1. Decompensated heart failure (hospitalization for heart failure within the 2 weeks
prior to screening) or between screening and randomization

2. History of type 1 diabetes

3. Major change in diuretic management during 48 hours prior to screening visit or 48
hours prior to randomization visit. (major change defined by doubling of diuretic dose
or addition of another diuretic medications)

4. Significant variability in baseline PA diastolic pressures during screening period.
Defined as changes greater than +/- 6 mmHg from average PA diastolic pressure during
week 1 of the screening phase and average PA diastolic pressure during week 2 of the
screening phase for those patients with an average baseline PA diastolic pressure
during week 1 of the screening phase of <30 mmHg. If the average baseline PA diastolic
pressure during week 1 of the screening phase is ≥30 mmHg, then ≥20% relative change
in average PA diastolic pressure between week 1 and week 2 of the screening phase will
be used to define significant variability.

5. Initiation of hydralazine, long-acting nitrates, beta blockers, ACEI/ARBs or
Valsartan/sacubitril in the prior 4 weeks prior to screening

6. Estimated glomerular filtration rate (eGFR) < 30 mL/min/1.73 m2 at the screening visit

7. Admission for an acute coronary syndrome (ST-elevation MI, non-ST-elevation MI, or
unstable angina), percutaneous coronary intervention, or cardiac surgery within 30
days prior to the screening visit.

8. Implantation of cardiac resynchronization therapy (CRT) device within the previous 90
days.

9. Implantation of the CardioMEMs device within the past 2 weeks.

10. Planned cardiovascular revascularization (percutaneous intervention or surgical) or
major cardiac surgery (coronary artery bypass grafting, valve replacement, ventricular
assist device, cardiac transplantation, or any other surgery requiring thoracotomy),
or planned implantation of CRT device within the 90 days after the screening visit.

11. Participation in any interventional clinical trial (with an investigational drug or
device) that is not an observational registry within the 4 weeks prior to the
screening visit.

12. History of hypersensitivity to empagliflozin

13. For women of child-bearing potential: Current or planned pregnancy or currently
lactating

14. Life expectancy <1 year at the screening visit

15. Patients who are volume depleted based upon physical examination at the time of the
screening or randomization visit

16. PA diastolic pressure < 12 mmHg at the time of the screening visit (average of last
four measurements available prior to the screening visit).

17. Patients currently being treated with any SGLT-2 inhibitor (dapagliflozin,
canagliflozin, empagliflozin) or having received treatment with any SGLT-2 inhibitor
within the 8 weeks prior to the screening visit

18. Average supine systolic BP <90 mmHg at the screening or randomization visit

19. Current documented history of bladder cancer

20. Active Gross Hematuria

21. Heart failure due to restrictive cardiomyopathy, active myocarditis, constrictive
pericarditis, severe stenotic valve disease, and HOCM (hypertrophic obstructive
cardiomyopathy).

22. History of heart transplant.

23. Patients on heart transplant list as 1a and 1b status
We found this trial at
9
sites
Austin, Texas 78756
Phone: 512-206-3602
?
mi
from
Austin, TX
Click here to add this to my saved trials
1200 Moursund Street
Houston, Texas 77030
(713) 798-4951
Phone: 713-798-1037
Baylor College of Medicine Baylor College of Medicine in Houston, the only private medical school...
?
mi
from
Houston, TX
Click here to add this to my saved trials
Los Angeles, California 90033
213) 740-2311
Phone: 323-442-7983
University of Southern California The University of Southern California is one of the world’s leading...
?
mi
from
Los Angeles, CA
Click here to add this to my saved trials
281 W. Lane Ave
Columbus, Ohio 43210
(614) 292-6446
Phone: 614-247-7133
Ohio State University The Ohio State University’s main Columbus campus is one of America’s largest...
?
mi
from
Columbus, OH
Click here to add this to my saved trials
Evanston, Illinois 60201
Phone: 847-570-2912
?
mi
from
Evanston, IL
Click here to add this to my saved trials
Jacksonville, Florida 32216
Phone: 904-493-3333
?
mi
from
Jacksonville, FL
Click here to add this to my saved trials
Norfolk, Virginia 23507
Phone: 757-388-2732
?
mi
from
Norfolk, VA
Click here to add this to my saved trials
Roslyn, New York 11576
Phone: 516-562-6790
?
mi
from
Roslyn, NY
Click here to add this to my saved trials
1406 6th Avenue North
Saint Cloud, Minnesota 56303
Phone: 320-251-2700
?
mi
from
Saint Cloud, MN
Click here to add this to my saved trials